$SYRA
Syra Health Corp

2023 Q4 Form 10-Q Financial Statement

#000149315223040869 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023 Q2
Revenue $1.766M $1.581M $980.0K
YoY Change -68.56% 4.45% -17.65%
Cost Of Revenue $1.184M $1.027M $850.0K
YoY Change -74.01% -6.67% -21.3%
Gross Profit $582.0K $554.5K $130.0K
YoY Change -45.18% 34.01% 18.18%
Gross Profit Margin 32.95% 35.07% 13.27%
Selling, General & Admin $1.316M $234.1K $900.0K
YoY Change -58.05% 55.55% 23.29%
% of Gross Profit 226.07% 42.21% 692.31%
Research & Development $240.1K
YoY Change
% of Gross Profit 41.24%
Depreciation & Amortization $12.36K $12.36K $10.00K
YoY Change 23.6% 218.48%
% of Gross Profit 2.12% 2.23% 7.69%
Operating Expenses $1.568M $897.6K $910.0K
YoY Change -50.24% 18.01% 24.66%
Operating Profit -$986.2K -$343.0K -$780.0K
YoY Change -52.81% -1.09% 25.81%
Interest Expense -$9.120K $14.18K -$20.00K
YoY Change -67.97% 82.29% 100.0%
% of Operating Profit
Other Income/Expense, Net -$11.36K -$18.85K
YoY Change 46.69%
Pretax Income -$995.3K -$354.4K -$800.0K
YoY Change -53.01% 26.98%
Income Tax
% Of Pretax Income
Net Earnings -$995.3K -$354.4K -$800.0K
YoY Change -53.01% -0.04% 26.98%
Net Earnings / Revenue -56.35% -22.41% -81.63%
Basic Earnings Per Share -$0.08 -$0.18
Diluted Earnings Per Share -$0.16 -$0.08 -$0.13
COMMON SHARES
Basic Shares Outstanding 13.92M shares 4.360M shares 4.379M shares
Diluted Shares Outstanding 4.360M shares 4.379M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.280M $18.01K $40.00K
YoY Change
Cash & Equivalents $3.280M $18.01K $36.45K
Short-Term Investments
Other Short-Term Assets $389.8K $163.3K
YoY Change 75.34%
Inventory
Prepaid Expenses $316.7K
Receivables $1.111M $1.055M $410.0K
Other Receivables $389.8K $163.3K $200.0K
Total Short-Term Assets $4.781M $1.236M $650.0K
YoY Change 235.11%
LONG-TERM ASSETS
Property, Plant & Equipment $142.2K $91.33K $230.0K
YoY Change 26.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $1.185M $920.0K
YoY Change
Total Long-Term Assets $142.2K $1.371M $1.150M
YoY Change -84.08%
TOTAL ASSETS
Total Short-Term Assets $4.781M $1.236M $650.0K
Total Long-Term Assets $142.2K $1.371M $1.150M
Total Assets $4.923M $2.607M $1.800M
YoY Change 112.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $463.0K $954.2K $660.0K
YoY Change
Accrued Expenses $262.2K $274.6K $260.0K
YoY Change 9.65%
Deferred Revenue
YoY Change
Short-Term Debt $184.9K $916.6K $300.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $910.1K $2.381M $1.220M
YoY Change -41.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.455M $1.460M
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $1.455M $1.460M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $910.1K $2.381M $1.220M
Total Long-Term Liabilities $0.00 $1.455M $1.460M
Total Liabilities $910.1K $3.836M $2.670M
YoY Change -43.46%
SHAREHOLDERS EQUITY
Retained Earnings -$5.065M -$4.070M
YoY Change 138.17%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.013M -$1.229M -$876.0K
YoY Change
Total Liabilities & Shareholders Equity $4.923M $2.607M $1.800M
YoY Change 112.24%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$995.3K -$354.4K -$800.0K
YoY Change -53.01% -0.04% 26.98%
Depreciation, Depletion And Amortization $12.36K $12.36K $10.00K
YoY Change 23.6% 218.48%
Cash From Operating Activities -$1.757M -$372.0K -$580.0K
YoY Change 9.13% 31.82%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$4.750K $10.00K
YoY Change -100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $4.750K -$10.00K
YoY Change -100.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.019M 351.9K 30.00K
YoY Change 606.92% -95.24%
NET CHANGE
Cash From Operating Activities -1.757M -372.0K -580.0K
Cash From Investing Activities 0.000 4.750K -10.00K
Cash From Financing Activities 5.019M 351.9K 30.00K
Net Change In Cash 3.262M -15.34K -560.0K
YoY Change -422.98% -411.11%
FREE CASH FLOW
Cash From Operating Activities -$1.757M -$372.0K -$580.0K
Capital Expenditures $0.00 -$4.750K $10.00K
Free Cash Flow -$1.757M -$367.3K -$590.0K
YoY Change 2.15% 31.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Prepaid Rent
PrepaidRent
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001922335
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q3 SYRA Stock Issued During Period Value Awarded Issued For Services
StockIssuedDuringPeriodValueAwardedIssuedForServices
usd
CY2022Q3 SYRA Stock Issued During Period Value Awarded Issued For Services
StockIssuedDuringPeriodValueAwardedIssuedForServices
usd
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
SYRA Initial Recognition Of Rightofuse Asset And Lease Liability
InitialRecognitionOfRightofuseAssetAndLeaseLiability
usd
CY2023Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2022Q4 SYRA Employee Retention Tax Credit Receivables
EmployeeRetentionTaxCreditReceivables
usd
CY2023Q3 SYRA Economic Development For A Growing Economy Receivables
EconomicDevelopmentForAGrowingEconomyReceivables
usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41822
dei Entity Registrant Name
EntityRegistrantName
SYRA HEALTH CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4027995
dei Entity Address Address Line1
EntityAddressAddressLine1
1119 Keystone Way N. #201
dei Entity Address City Or Town
EntityAddressCityOrTown
Carmel
dei Entity Address State Or Province
EntityAddressStateOrProvince
IN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
46032
dei City Area Code
CityAreaCode
(463)
dei Local Phone Number
LocalPhoneNumber
345-8950
dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
Not applicable
dei Security12b Title
Security12bTitle
Class A Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
SYRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13921638 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18010 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3344 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1054851 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1201097 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
163323 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
222302 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1236184 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1426743 usd
CY2023Q3 us-gaap Deferred Costs
DeferredCosts
1185177 usd
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
596118 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91331 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112493 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
94126 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
184288 usd
CY2023Q3 us-gaap Assets
Assets
2606818 usd
CY2022Q4 us-gaap Assets
Assets
2319642 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
274596 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
239117 usd
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
141644 usd
CY2023Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
300154 usd
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
750551 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2381119 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1546345 usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1455000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
3836119 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1609544 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 SYRA Preferred Stock Shares Designated
PreferredStockSharesDesignated
0 shares
CY2022Q4 SYRA Preferred Stock Shares Designated
PreferredStockSharesDesignated
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2836019 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2832308 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4069680 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2126612 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1229301 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
710098 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2606818 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2319642 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1581344 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1513979 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3748943 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3651978 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1026803 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1100170 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2919087 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2881142 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
554541 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
413809 usd
us-gaap Gross Profit
GrossProfit
829856 usd
us-gaap Gross Profit
GrossProfit
770836 usd
CY2023Q3 us-gaap Salaries And Wages
SalariesAndWages
592241 usd
CY2022Q3 us-gaap Salaries And Wages
SalariesAndWages
451771 usd
us-gaap Salaries And Wages
SalariesAndWages
1612605 usd
us-gaap Salaries And Wages
SalariesAndWages
1021627 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
58875 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
154457 usd
us-gaap Professional Fees
ProfessionalFees
424379 usd
us-gaap Professional Fees
ProfessionalFees
863297 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
234084 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
150492 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
657904 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
370067 usd
CY2023Q3 us-gaap Depreciation
Depreciation
12357 usd
CY2022Q3 us-gaap Depreciation
Depreciation
3880 usd
us-gaap Depreciation
Depreciation
36413 usd
us-gaap Depreciation
Depreciation
4791 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
897557 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
760600 usd
us-gaap Operating Expenses
OperatingExpenses
2731301 usd
us-gaap Operating Expenses
OperatingExpenses
2259782 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-343016 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-346791 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1901445 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1488946 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2820 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
35 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2826 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
54 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
14180 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
7779 usd
us-gaap Interest Expense
InterestExpense
44449 usd
us-gaap Interest Expense
InterestExpense
16641 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11360 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7744 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41623 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16587 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-354376 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-354535 usd
us-gaap Net Income Loss
NetIncomeLoss
-1943068 usd
us-gaap Net Income Loss
NetIncomeLoss
-1505533 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4360426 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4360426 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4107164 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4107164 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4380267 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4380267 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2337915 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2337915 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-876004 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1079 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-354376 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1229301 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1159435 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
514920 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1151 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-354535 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1320971 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
710098 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3669 usd
us-gaap Net Income Loss
NetIncomeLoss
-1943068 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1229301 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-7147 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2322500 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2322500 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
510000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
510000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1151 usd
us-gaap Net Income Loss
NetIncomeLoss
-1505533 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1320971 usd
us-gaap Net Income Loss
NetIncomeLoss
-1943068 usd
us-gaap Net Income Loss
NetIncomeLoss
-1505533 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
90162 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
66361 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
9922 usd
us-gaap Depreciation
Depreciation
36413 usd
us-gaap Depreciation
Depreciation
4791 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10115 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
510000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3669 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1151 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-136324 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
355483 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-58979 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
110342 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
500391 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
258349 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
18221 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-82418 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
35479 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
246709 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
141644 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-90162 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-66361 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1002026 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1022661 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15251 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
76358 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15251 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-76358 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
589059 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
446688 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2322500 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
300000 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
1321275 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
750397 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1335351 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1295010 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
94000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
678611 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
288200 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1455000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1031943 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1667536 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14666 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
568517 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3344000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100012000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18010000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
668529000 usd
us-gaap Interest Paid Net
InterestPaidNet
28533000 usd
us-gaap Interest Paid Net
InterestPaidNet
6526000 usd
SYRA Initial Recognition Of Rightofuse Asset And Lease Liability
InitialRecognitionOfRightofuseAssetAndLeaseLiability
131187 usd
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-1.2
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zGYRYDkgZzUd" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zcwxQpzmptF4">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SYRA HEALTH CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zBlfDI87HRp7" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zvGn6PdWImU7">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zMOWIeY8CaL8" title="FDIC Insured amount">250,000</span> under current regulations. The Company did not have any cash in excess of FDIC insured limits at September 30, 2023. The Company has not experienced any losses in such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
5520 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
4533 usd
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
589059 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
596118 usd
CY2023Q3 SYRA Employee Retention Tax Credit Receivables
EmployeeRetentionTaxCreditReceivables
50000 usd
CY2022Q4 SYRA Economic Development For A Growing Economy Receivables
EconomicDevelopmentForAGrowingEconomyReceivables
116361 usd
CY2023Q3 us-gaap Prepaid Taxes
PrepaidTaxes
23069 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
28734 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
41747 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
20040 usd
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
10711 usd
CY2023Q3 SYRA Prepaid Licensing And Office Fees
PrepaidLicensingAndOfficeFees
44397 usd
CY2022Q4 SYRA Prepaid Licensing And Office Fees
PrepaidLicensingAndOfficeFees
16456 usd
CY2023Q3 SYRA Retainers Paid On Professional Services
RetainersPaidOnProfessionalServices
4110 usd
CY2022Q4 SYRA Retainers Paid On Professional Services
RetainersPaidOnProfessionalServices
30000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
163323 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
222302 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
51469 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15056 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91331 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112493 usd
us-gaap Depreciation
Depreciation
36413 usd
us-gaap Depreciation
Depreciation
4791 usd
CY2023Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
249403 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
212660 usd
CY2023Q3 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
3759 usd
CY2022Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
4874 usd
CY2023Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
2712 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
18777 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
18722 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2806 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
274596 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
239117 usd
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1 pure
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04 pure
SYRA Inflation Reduction Amount
InflationReductionAmount
66590 usd
CY2023Q3 SYRA Accrued Retirement Contributions
AccruedRetirementContributions
3759 usd
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
141644 usd
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
150000 usd
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
150000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
90162 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
66361 usd
SYRA Operating Lease Interest Expense
OperatingLeaseInterestExpense
6233 usd
SYRA Operating Lease Interest Expense
OperatingLeaseInterestExpense
8520 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
96395 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
74881 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
94126 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
184288 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
94126 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
121089 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
63199 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
94126 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
184288 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575 pure
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575 pure
us-gaap Operating Lease Payments
OperatingLeasePayments
90162 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
66361 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
32132 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
64263 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
96395 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2269 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
94126 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
94126 usd
CY2023Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
300154 usd
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
750551 usd
CY2023Q3 us-gaap Line Of Credit
LineOfCredit
301655 usd
CY2023Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
300154 usd
us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
1501 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
3792000 usd
CY2023Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
3792000 usd

Files In Submission

Name View Source Status
0001493152-23-040869-index-headers.html Edgar Link pending
0001493152-23-040869-index.html Edgar Link pending
0001493152-23-040869.txt Edgar Link pending
0001493152-23-040869-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
log_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syra-20230930.xsd Edgar Link pending
syra-20230930_def.xml Edgar Link unprocessable
syra-20230930_lab.xml Edgar Link unprocessable
syra-20230930_cal.xml Edgar Link unprocessable
syra-20230930_pre.xml Edgar Link unprocessable